| (Values in U.S. Thousands) | Jun, 2026 | Jun, 2025 | Aug, 2026 | Aug, 2026 | Aug, 2026 |
| Sales | 847,979 | 1,142,289 | 0 | 0 | 0 |
| Sales Growth | -25.76% | unch | unch | unch | unch |
| Net Income | -38,345 | 362,700 | 0 | 0 | 0 |
| Net Income Growth | -110.57% | unch | unch | unch | unch |
Apotex Health Corp (APTX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Apotex Health Corp is a Canadian-based health company with a broad portfolio of generic, biosimilar and branded pharmaceuticals, as well as branded consumer health and wellness products. Its business lines include Conventional Generics, Specialty Generics and Brands & Biosimilars. The maximum revenue is derived from the Conventional Generics business, which are off-patent, small molecule oral solid dose pharmaceuticals that are bioequivalent to branded pharmaceuticals. It has three geographic operating segments: (i) Canada; (ii) the U.S.; and (iii) International. The majority of revenue is derived from Canada.
Fiscal Year End Date: 03/31